Drugmakers should have to release complete trial data

04/11/2012 | New York Times (tiered subscription model), The

Drugmakers in the U.S. are not required to release full clinical trial reports to researchers or the public, and the FDA does not disclose the data that regulators review in the drug approval process. The result can be use of a drug based on incomplete data published in journal articles, potentially at great public expense, as in the case of Roche Holding's Tamiflu, write research fellow Peter Doshi and epidemiologist Tom Jefferson. The European Medicines Agency intends to release clinical study data after regulators review a manufacturer's application, and the FDA should follow suit, the scientists argue.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ